0001140361-17-037828.txt : 20171006
0001140361-17-037828.hdr.sgml : 20171006
20171006183734
ACCESSION NUMBER: 0001140361-17-037828
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171004
FILED AS OF DATE: 20171006
DATE AS OF CHANGE: 20171006
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCarthy Sean A.
CENTRAL INDEX KEY: 0001654058
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 171128329
MAIL ADDRESS:
STREET 1: 343 OYSTER POINT BLVD.
STREET 2: SUITE 100
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2017-10-04
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001654058
McCarthy Sean A.
151 OYSTER POINT BLVD.
SUITE 400
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
2017-10-04
4
M
0
19120
0.945
A
23365
D
Common Stock
2017-10-04
4
S
0
19120
24.13
D
4245
D
Common Stock
158737
I
See footnote
Common Stock
0.945
2017-10-04
4
M
0
19120
0
D
2023-02-25
Common Stock
19120
133635
D
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.51 to $24.39, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.
100% of the shares subject to the option are fully vested and exercisable.
Previous Form 4s filed by the Reporting Person included an error in the number of securities beneficially owned by the Reporting Person in Table II, Box 9. The number of derivative securities beneficially owned as reported in Table II, Box 9 of this Form 4 has been adjusted to correct the previous errors and reflects the current number of derivative securities beneficially owned as of this filing date.
/s/ Cynthia J. Ladd, as Attorney-in-Fact for Sean A. McCarthy
2017-10-06